TRACON PHARMACEUTICALS INC (TCON) Stock Price, Forecast & Analysis
USA - NASDAQ:TCON - US89237H3084 - Common Stock
TCON Key Statistics, Chart & Performance
The current stock price of TCON is 1.43 USD. In the past month the price decreased by -5.3%. In the past year, price decreased by -75.43%.
TCON Latest News, Press Relases and Analysis
TCON Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 20.59 | 385.18B | ||
| AMGN | AMGEN INC | 13.68 | 160.66B | ||
| GILD | GILEAD SCIENCES INC | 14.63 | 148.64B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.12 | 109.11B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.48 | 69.08B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 350.8 | 59.78B | ||
| ARGX | ARGENX SE - ADR | 61.77 | 50.39B | ||
| INSM | INSMED INC | N/A | 40.08B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.01 | 34.10B | ||
| NTRA | NATERA INC | N/A | 27.30B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.98B | ||
| BIIB | BIOGEN INC | 9.22 | 22.62B |
Related stock screener links
About TCON
Company Profile
TRACON Pharmaceuticals, Inc. engages in the development and commercialization of targeted therapies for cancer, and ophthalmic and fibrotic diseases. The company is headquartered in San Diego, California and currently employs 18 full-time employees. The company went IPO on 2015-01-30. The firm is focused on the development and commercialization of targeted therapeutics for cancer. The Company’s lead product candidate, envafolimab, is a PD-L1 antibody that is being developed for the treatment of sarcoma. The Company’s other product candidates are YH001, a CTLA-4 antibody that is in Phase I/II development for the treatment of sarcoma; TRC102, a small molecule that is in Phase II clinical development for the treatment of mesothelioma; TJ004309, a CD73 antibody that is in Phase I testing, that is being developed through a collaboration with I-Mab Biopharma, and multiple bispecific antibody programs in preclinical development that are being developed through a collaboration with I-Mab Biopharma. The firm offers partners a solution for the clinical development and commercialization of their products in the United States.
Company Info
TRACON PHARMACEUTICALS INC
4350 La Jolla Village Drive, Suite 800
San Diego CALIFORNIA 92122 US
CEO: Charles P. Theuer
Employees: 18
Phone: 18585500780
TRACON PHARMACEUTICALS INC / TCON FAQ
Can you describe the business of TRACON PHARMACEUTICALS INC?
TRACON Pharmaceuticals, Inc. engages in the development and commercialization of targeted therapies for cancer, and ophthalmic and fibrotic diseases. The company is headquartered in San Diego, California and currently employs 18 full-time employees. The company went IPO on 2015-01-30. The firm is focused on the development and commercialization of targeted therapeutics for cancer. The Company’s lead product candidate, envafolimab, is a PD-L1 antibody that is being developed for the treatment of sarcoma. The Company’s other product candidates are YH001, a CTLA-4 antibody that is in Phase I/II development for the treatment of sarcoma; TRC102, a small molecule that is in Phase II clinical development for the treatment of mesothelioma; TJ004309, a CD73 antibody that is in Phase I testing, that is being developed through a collaboration with I-Mab Biopharma, and multiple bispecific antibody programs in preclinical development that are being developed through a collaboration with I-Mab Biopharma. The firm offers partners a solution for the clinical development and commercialization of their products in the United States.
Can you provide the latest stock price for TRACON PHARMACEUTICALS INC?
The current stock price of TCON is 1.43 USD. The price decreased by -1.38% in the last trading session.
Does TRACON PHARMACEUTICALS INC pay dividends?
TCON does not pay a dividend.
What is the ChartMill rating of TRACON PHARMACEUTICALS INC stock?
TCON has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
How is the market expecting TCON stock to perform?
9 analysts have analysed TCON and the average price target is 31.11 USD. This implies a price increase of 2075.52% is expected in the next year compared to the current price of 1.43.
What sector and industry does TRACON PHARMACEUTICALS INC belong to?
TRACON PHARMACEUTICALS INC (TCON) operates in the Health Care sector and the Biotechnology industry.
What is the market capitalization of TCON stock?
TRACON PHARMACEUTICALS INC (TCON) has a market capitalization of 3.83M USD. This makes TCON a Nano Cap stock.
TCON Technical Analysis
TCON Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to TCON. The financial health of TCON is average, but there are quite some concerns on its profitability.
TCON Financial Highlights
Over the last trailing twelve months TCON reported a non-GAAP Earnings per Share(EPS) of 9.07. The EPS increased by 808.59% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 14.39% | ||
| ROA | 18.69% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
TCON Forecast & Estimates
9 analysts have analysed TCON and the average price target is 31.11 USD. This implies a price increase of 2075.52% is expected in the next year compared to the current price of 1.43.
For the next year, analysts expect an EPS growth of -142.4% and a revenue growth -100% for TCON